Ph.D. Program for Cancer Molecular Biology and Drug Discovery

  • No. 250 Wu-Xing Street

    11031 Taipei

Organization profile

Organisation profile

This doctoral research program was established in collaboration with Academia Sinica to cultivate interdisciplinary research that focuses on tumor-related medicine. Academia Sinica is Taiwan’s leading research institute and has outstanding scientific researchers and cutting-edge equipment for advanced research. TMU also works in collaboration with its three affiliated hospitals and has access to their clinical resources.

Through these relationships, the Cancer Biology and Drug Discovery program offers students a great opportunity to build a career with excellent research support. We enroll top students from around the world, and provide a strong curriculum of interdisciplinary training as well as a learning environment where students work with many research specialists.

From basic research to translational medicine, we develop cutting-edge therapeutic strategies for cancer prevention and treatment. We work hard for cancer patients, seeking to extend their lives and improve their quality of life.

Fingerprint Dive into the research topics where Ph.D. Program for Cancer Molecular Biology and Drug Discovery is active. These topic labels come from the works of this organisation's members. Together they form a unique fingerprint.

Neoplasms Medicine & Life Sciences
Colorectal Neoplasms Medicine & Life Sciences
Prostatic Neoplasms Medicine & Life Sciences
Cells Chemical Compounds
MicroRNAs Medicine & Life Sciences
Thyroid Hormones Medicine & Life Sciences
Apoptosis Medicine & Life Sciences
Non-Small Cell Lung Carcinoma Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Projects 2012 2019

研究去勢療法之後的前列腺癌病變及發展阻斷發炎的癌症免疫療法

Tsai, Y.

8/1/187/31/19

Project: A - Government Institutionb - Ministry of Science and Technology

基於片段的藥物探索方法開發新一類抗癌標靶小分子激酶抑制劑(2/2)

Huang, H.

8/1/187/31/19

Project: A - Government Institutionb - Ministry of Science and Technology

新穎性選擇性HDAC抑制劑之抗癌藥物開發與藥理機轉探討(1/3)

Pan, S.

8/1/187/31/19

Project: A - Government Institutionb - Ministry of Science and Technology

Research Output 1996 2019

2 Citations (Scopus)

1-Arylsulfonyl indoline-benzamides as a new antitubulin agents, with inhibition of histone deacetylase

Lai, M. J., Ojha, R., Lin, M. H., Liu, Y. M., Lee, H. Y., Lin, T. E., Hsu, K. C., Chang, C. Y., Chen, M. C., Nepali, K., Chang, J. Y. & Liou, J. P., Jan 15 2019, In : European Journal of Medicinal Chemistry. 162, p. 612-630 19 p.

Research output: Contribution to journalArticle

Benzamides
Histone Deacetylases
Tubulin
Heterografts
Inhibitory Concentration 50
1 Citation (Scopus)

Action of Reverse T3 on Cancer Cells

Lin, H. Y., Tang, H. Y., Leinung, M., Mousa, S. A., Hercbergs, A. & Davis, P. J., Jan 1 2019, In : Endocrine Research.

Research output: Contribution to journalArticle

Integrins
Thyronines
Thyroid Hormone Receptors
Neoplasms
Glioblastoma

Alternative splicing in human cancer cells is modulated by the amiloride derivative 3,5-diamino-6-chloro-N-(N-(2,6-dichlorobenzoyl)carbamimidoyl)pyrazine-2-carboxide

Lee, C. C., Chang, W. H., Chang, Y. S., Yang, J. M., Chang, C. S., Hsu, K. C., Chen, Y. T., Liu, T. Y., Chen, Y. C., Lin, S. Y., Wu, Y. C. & Chang, J. G., Jan 1 2019, In : Molecular Oncology.

Research output: Contribution to journalArticle

Open Access
Pyrazines
Amiloride
Alternative Splicing
Neoplasms
RNA Sequence Analysis